8th May 2019 12:11
LONDON (Alliance News) - MaxCyte Inc on Wednesday said it has begun dosing for the second cohort of patients in its phase one trial of cancer drug MCY-M11.
Shares in MaxCyte were down 5.7% at 170.00 pence in trading before noon.
The non-randomised open label trial is assessing the safety and effectiveness of MCY-M11 in patients with advanced ovarian, primary peritoneum, or fallopian tube cancer that is resistant to treatment.
Around 15 participants will be enrolled in the study, which will take place in the US. Thus far in the first cohort, no dose-limiting toxicities or safety concerns have been found.
MCY-M11 is the leading candidate from MaxCyte's Carma platform. Carma uses manufacturing process that enables fast turnaround on cell therapy, the goal of which is to trigger the patient's own immune system to fight diseases.
"Successfully completing patient dosing in our first cohort and initiating dosing in a second higher-dose cohort are important milestones for MaxCyte, representing tangible progress for our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform," said Claudio Ullmann, chief medical officer at MaxCyte.
"We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumours where the majority of patients still have very limited treatment options," Ullmann added.
Related Shares:
MaxCyte